Clinical characteristics and outcomes of psoriasis patients with COVID-19:A retrospective,multicenter cohort study in ChinaOACSTPCDMEDLINE

Background:Limited information exists regarding the impact of severe acute respiratory syndrome-coronavirus-2(SARS-CoV-2)infection on psoriasis patients.The objective of this study was to identify clinical factors associated with the prognosis of psoriasis following SARS-CoV-2 infection. Methods:A retrospective,multicenter study was conducted between March and May 2023.Univariable and multivariable logistic regression analyses were employed to identify factors associated with coronavirus disease 2019(COVID-19)-related psoriasis out-comes.The study included 2371 psoriasis patients from 12 clinical centers,with 2049 of them having been infected with SARS-CoV-2. Results:Among the infected groups,lower exacerbation rates were observed in individuals treated with biologics compared to those receiving traditional systemic or nonsystemic treatments(22.3％[236/1058]vs.39.8％[92/231]vs.37.5％[140/373],P＜0.001).Psoriasis progression with lesions(adjusted odds ratio[OR]=8.197,95％confidence interval[95％CI]=5.685-11.820,compared to no lesions),hypertension(adjusted OR=1.582,95％CI=1.068-2.343),traditional systemic(adjusted OR=1.887,95％CI=1.263-2.818),and nonsystemic treatment(adjusted OR=1.602,95％CI=1.117-2.297)were found to be associated with exacerbation of psoriasis after SARS-CoV-2 infection,but not biologics(adjusted OR=0.931,95％CI=0.680-1.274,compared to no treatment),according to multivariable logistic regression analysis. Conclusions:A reduced risk of psoriasis exacerbation after SARS-CoV-2 infection was observed with biologics compared to traditional systemic and nonsystemic treatments.Significant risk factors for exacerbation after infection were identified as existing psoriatic lesions and hypertension.